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The increasing prevalence of congestive heart failure has
focused importance on the search for potentially reversible etiol-
ogies of cardiomyopathy. The concept that incessant or chronic
tachycardias can lead to ventricular dysfunction that is reversible
is supported by both animal models of chronic rapid pacing as
well as human studies documenting improvement in ventricular
function with tachycardia rate or rhythm control. Sustained rapid
pacing in experimental animal models can produce severe biven-
tricular systolic dysfunction. Hemodynamic changes occur as
soon as 24 h after rapid pacing, with continued deterioration
in ventricular function for up to 3 to 5 weeks, resulting in
end-stage heart failure. The recovery from pacing-induced cardio-
myopathy demonstrates that the myopathic process associated
with rapid heart rates is largely reversible. Within 48 h after
termination of pacing, hemodynamic variables approach control
levels, and left ventricular ejection fraction shows significant
recovery with subsequent normalization after 1 to 2 weeks. In
humans, descriptions of reversal of cardiomyopathy with rate or
rhythm control of incessant or chronic tachycardias have been
reported with atrial tachycardias, accessory pathway reciprocat-
ing tachycardias, atrioventricular (AV) node reentry and atrial
fibrillation (AF) with rapid ventricular responses. Control of AF
rapid ventricular responses has been demonstrated to improve
ventricular dysfunction with cardioversion to sinus rhythm, phar-
macologic ventricular rate control and AV junction ablation and
permanent ventricular pacing. The investigation of potential
tachycardia-induced cardiomyopathy in patients with heart fail-
ure requires further prospective confirmation in larger numbers
of patients, with study of mechanisms, patient groups affected and
optimal therapies.
(J Am Coll Cardiol 1997;29:709–15)
q1997 by the American College of Cardiology
Congestive heart failure is a major health care problem,
affecting 1 to 2 million adults in the United States (1). Hospital
admissions for congestive heart failure have more than dou-
bled over the past two decades due to the increased average
age of the U.S. population as well as the greater duration of
survival of patients with chronic heart disease (2). Given the
enormity of this problem, reversible causes of depressed left
ventricular systolic function should be vigorously investigated.
The effect of tachyarrhythmias on ventricular structure and
function is an important area of research because incessant or
chronic tachyarrhythmias may cause a tachycardia-induced
cardiomyopathy that may be reversible with tachycardia rate or
rhythm control. The goal of this review is to summarize 1) the
pathophysiologic aspects of pacing-induced heart failure in
experimental models; and 2) clinical evidence to support the
concept of tachycardia-induced cardiomyopathy.
Animal Models
Experimental tachycardia-induced cardiomyopathy was first
described by Whipple et al. (3) in 1962. Although first devised
to mimic tachycardia-induced cardiomyopathy in humans, the
model has been invaluable to the general study of heart failure
by providing a predictable stable model of low output biven-
tricular failure (4–11). Specifically with regard to tachycardia-
mediated cardiomyopathy, the model allows study of the effect
of chronic rapid pacing on ventricular function, as well as the
recovery phase associated with discontinuance of rapid pacing.
The progression and reversal of heart failure demonstrate
time, rate and species dependency. The dog and pig models are
most widely studied and are the basis for this discussion.
Hemodynamic Changes
Sustained rapid atrial or ventricular pacing can produce
severe biventricular systolic and diastolic dysfunction in animal
models. By pacing at a slower rate or for a shorter duration, a
lesser degree of left ventricular dysfunction can be produced
(8,12,13). The heart failure is characterized by markedly
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elevated ventricular filling pressures (14–16), and severe im-
pairment of left ventricular (up to 55% reduction) and right
ventricular systolic function (9,10,16–18). Cardiac output is
severely reduced, and systemic vascular resistance is typically
elevated (6,7,14,17). Left ventricular systolic wall stress is
markedly elevated (12,17,19,20). Moderate mitral regurgita-
tion may develop late in the evolution of heart failure (14). As
with other forms of severe heart failure, intense neurohumoral
activation is produced with marked elevations of plasma atrial
natriuretic peptide, epinephrine, norepinephrine, renin activity
and aldosterone (5,21) levels.
The marked ventricular systolic dysfunction results from
intrinsic loss of myocardial contractility as assessed by whole-
heart and isolated myocyte indexes (15,19,20,22–25). Contrac-
tile reserve in response to inotropic agents, volume loading and
post-extrasystolic potentiation is diminished or absent (22,25–
29). Diminished cardiac sympathetic responsiveness is demon-
strable and may be due to a markedly reduced myocyte
beta1-receptor density and postreceptor abnormalities of ade-
nylate cyclase and calcium handling (30,31). The data relating
to diastolic dysfunction during pacing-induced heart failure are
discordant. Multiple studies have demonstrated that whole-
heart indexes of diastolic function may be normalized by
inotropic agents or correction of loading conditions (24,32,33);
however, recent isolated myocyte research has shown primary
impairment of intrinsic myocardial relaxation at the cellular
level (34).
Cardiac Structural Changes
Chronic rapid pacing produces a markedly dilated cardio-
myopathy involving all cardiac chambers. Left ventricular
dilation is more marked for end-systolic than end-diastolic
volumes (9,17) and produces a spherical chamber geometry
(14,15,23). This profound cardiac dilation is typically accom-
panied by right and left ventricular wall thinning or preserva-
tion of wall thickness without either hypertrophy (14,19) or
consistent increases in heart weight (7,15,23). However, there
are data demonstrating a differential response between the
ventricles, with evidence of pacing-induced right ventricular
hypertrophy without associated left ventricular hypertrophy
(35).
On the cellular level, both myocyte and extracellular matrix
remodeling have been documented. With rapid pacing, disrup-
tion of both the extracellular matrix architecture and the
myocyte basement membrane–sarcolemmal interface occurs
(10,22,36–38). The disordered extracellular matrix compro-
mises myocyte alignment, force coupling and transmission
and capillary patency, with resultant chamber dilation, wall
thinning and contractile dysfunction characteristic of this
model (37). Morphologic changes in myocytes themselves that
have been reported include myocyte loss, cellular elongation,
myofibril misalignment and loss of sarcomere register
(10,22,37,38). In a recent study demonstrating chamber dila-
tion and mural thinning in the absence of gross changes in
cardiac weight, the cellular basis of remodeling was a 39% loss
of myocytes and a 61% increase in volume of remaining
myocytes (38). However, the issue regarding myocyte death
and hypertrophy remains to be conclusively established be-
cause other studies have shown remodeling without evidence
of myocyte hypertrophy (39). A shift from myocyte contractile
to cytoskeletal protein synthesis has been reported (40).
Time Course and Recovery
After 24 h of rapid pacing, systemic arterial pressure and
cardiac output are reduced (7,41). With continued pacing,
increasing intracardiac filling and pulmonary artery pressures
and decreasing systemic arterial pressures typically plateau at 1
week, whereas cardiac output, ejection fraction and cardiac
volumes may continually deteriorate for up to 3 to 5 weeks with
development of end-stage heart failure (5,8,14,16).
The recovery from pacing-induced heart failure is a dra-
matic and unique feature of this model, revealing that the
myopathic process associated with rapid heart rates is largely
reversible. Within 48 h after termination of pacing, right atrial
and mean arterial pressures, cardiac index and systemic vascu-
lar resistance approach control levels (12). Left ventricular
ejection fraction shows significant recovery by 24 to 48 h and
normalizes after 1 to 2 weeks (9,12); however, residual con-
tractile dysfunction is demonstrable in isolated myocytes at 4
weeks of recovery (42). Within 4 weeks, all hemodynamic
variables return to control levels; yet end-systolic and end-
diastolic volumes remain elevated at 12 weeks after termina-
tion of pacing, consistent with extensive ventricular remodeling
(8,9,17,23). Diastolic dysfunction remains measurable 4 weeks
after pacing (28). Interestingly, left ventricular hypertrophy
develops in the 4 weeks after discontinuance of pacing (23,42),
possibly owing to either the inability to respond to triggers for
hypertrophy during pacing itself or as compensatory remodel-
ing. The demonstrated proliferation of large collagen fiber
bundles after termination of pacing may contribute to the left
ventricular hypertrophy noted during recovery (37). The ability
to modulate the occurrence of ventricular hypertrophy may be
an invaluable feature of this model, leading to a better
understanding of the factors involved in the development of
myocardial hypertrophy.
Mechanisms for Cardiomyopathy
The precise mechanisms responsible for the contractile
dysfunction and structural changes of pacing-induced cardio-
myopathy are not known. Research to date has focused on 1)
myocardial energy depletion and impaired energy utilization;
2) myocardial ischemia; 3) abnormalities of cardiac calcium
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
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regulation; and 4) myocyte and extracellular matrix remodel-
ing. Myocardial energy depletion has been proposed as a
possible mechanism for myocardial dysfunction, and studies
have demonstrated reduced myocardial energy stores, includ-
ing creatine, phosphocreatine and adenosine triphosphate;
enhanced activity of Krebs cycle oxidative enzymes; mitochon-
drial structural injury; and mitochondrial functional abnormal-
ities, including diminished mitochondrial cytochrome oxidase
staining and creatine kinase activity associated with pacing-
induced cardiomyopathy (4,10,18,43,44). However, it is not
clear that these findings lead to cardiac dysfunction and may
merely be a secondary effect of rapid pacing. Similarly, myo-
cardial ischemia has been a proposed mechanism given supra-
physiologic heart rates, reduced systemic arterial pressure and
increased ventricular diastolic pressures. Although morpho-
logic and functional abnormalities of the coronary vasculature
have been demonstrated, including abnormal subendocardial
to subepicardial flow ratios and impaired coronary flow re-
serves (33,43,45,46), convincing primary roles for either myo-
cardial ischemia or energy depletion have not been established.
The role of abnormal calcium handling in mediating exper-
imental tachycardia-induced cardiomyopathy has received con-
siderable support. Extensive abnormalities of calcium channel
activity and sarcoplasmic reticulum calcium transport as as-
sessed by ryanodine receptor response, aequorin light genera-
tion and mechanical restitution kinetics may appear within
24 h of pacing and can persist at 4 weeks into recovery
(18,26,27,47). These abnormalities in calcium cycling are cor-
related in severity with the degree of ventricular dysfunction
(18). A downregulation of calcium cycling has been docu-
mented with lower activity of sarcoplasmic reticulum calcium
transport ATPase and myofibrillar calcium ATPase. This
downregulation is asymmetric, with the calcium channel being
more affected than the calcium pump (18,48). Although de-
rangement in calcium handling is an attractive and potentially
unifying mechanism for tachycardia-induced cardiomyopathy,
controversy exists as to how abnormalities of calcium regula-
tion may potentially lead to systolic dysfunction. Some groups
suggest that systolic dysfunction in pacing-induced cardiomy-
opathy may be due to decreased calcium sensitivity (27,29),
whereas others have shown increased calcium sensitivity and
suggest that abnormalities in excitation–contraction coupling
may instead be responsible for systolic dysfunction in this
model (49). In a recent report, tachycardia-induced cardiomy-
opathy was found to alter the recovery kinetics of sarcoplasmic
reticulum calcium release to a greater extent than calcium
sequestration, suggesting that the abnormal time course of
calcium availability to myofilaments is the rate-limiting step in
recovery of cardiac function (50). Determination of the respec-
tive mechanistic roles of calcium handling by the components
of the sarcoplasmic reticulum and the contractile apparatus in
pacing-induced cardiomyopathy requires further investigation.
Another intriguing proposed mechanism for pacing-
induced cardiomyopathy may involve the previously men-
tioned cellular and extracellular matrix remodeling that occurs
with rapid pacing. However, the adaptive or degenerative
nature of these morphologic changes remains to be deter-
mined.
Human Studies
Historical perspective. Although initial clues that incessant
or chronic tachyarrhythmias may lead to reversible ventricular
dysfunction date back to the early 1900s, prospective studies of
this relation did not begin until the early 1990s. In 1913
Gossage and Braxton Hicks (51) described a case of atrial
fibrillation (AF) in a young man who subsequently developed
left ventricular dilation and hypertrophy, suggesting that the
ventricular dilation and hypertrophy “might very well have
been a consequence not a cause of the auricular fibrillation.”
Reports in the 1930s through the 1940s documented cases of
complete resolution of congestive heart failure after cardiover-
sion of AF to sinus rhythm (52–54). Subsequent descriptions of
congestive heart failure associated with incessant atrial tachy-
cardia (55–57) and descriptions of reversible cardiomyopathy
associated with rate and rhythm control of AF with rapid
ventricular responses (58–62), atrial tachycardia (63–70), ac-
cessory pathway reciprocating tachycardias (66,67,71,72) and
atrioventricular (AV) node reentry (60,73) were reported. Addi-
tionally, reversible cardiomyopathy has been reported in the
treatment of incessant ventricular tachycardia (64,74).
Atrial fibrillation: restoration of sinus rhythm or ventric-
ular rate control. Because AF is a common arrhythmia in
patients with dilated heart failure, investigation of possible
tachycardia-induced cardiomyopathy has focused on this pop-
ulation. The effect of control of AF rapid ventricular responses
on cardiac function has been preliminarily investigated in
small, prospective studies of the following treatment modali-
ties: 1) cardioversion to sinus rhythm; 2) pharmacologic ven-
tricular rate control; and 3) AV junction ablation and perma-
nent ventricular pacing (Table 1).
The study of conversion of AF to sinus rhythm provides
information on changes associated with the resumption of
atrial contraction and AV synchrony leading to a regularized,
rate-controlled ventricular response. Previous studies have
documented improvement in cardiac output (75) and cardio-
pulmonary exercise testing variables of ventricular rate control,
maximal oxygen uptake and anaerobic threshold (76,77) after
cardioversion to sinus rhythm. More recently, a small, prospec-
tive study of patients with a diagnosis of “idiopathic” dilated
cardiomyopathy and chronic AF reported a significant increase
in left ventricular ejection fraction after pharmacologic or
electrical cardioversion to sinus rhythm (78). Whether im-
provement in cardiac function was due to restoration of atrial
systolic function and AV synchrony versus reversal of an
underlying cardiomyopathy associated with rapid and irregular
ventricular rates during AF was not resolved by this study.
Subsequent study of atrial and ventricular systolic function and
metabolic exercise testing before and serially after cardiover-
sion in patients with chronic AF with rapid baseline rest
ventricular responses demonstrated a dissociation between the
early normalization of effective atrial transport (1 day to 1
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week) from the much later normalization of left ventricular
ejection fraction and peak oxygen consumption (1 month),
suggesting that the delayed improvement in cardiac function
may be due to reversal of an intrinsic cardiomyopathy associ-
ated with AF rather than the contribution of atrial contraction
(79).
The effect of heart rate control alone on ventricular func-
tion independent of AV synchrony has been studied through
the use of AV junction ablation and permanent ventricular
pacing. This modality of therapy provides rate control with a
regular paced ventricular rhythm. The studies have provided
preliminary evidence that benefit can clearly occur without AV
synchrony in patients with initial rapid ventricular responses,
despite paced rather than spontaneous ventricular activation.
In patients with drug-refractory AF or atrial flutter and mildly
depressed ventricular function, rate control through radiofre-
quency energy AV junction ablation and permanent ventricu-
lar pacing provided a modest but significant increase in left
ventricular ejection fraction without a significant change in
treadmill exercise time (80). In a study of patients with AF and
ventricular responses .120 beats/min for the majority of the
day, left ventricular fractional shortening improved signifi-
cantly in the patients with baseline depressed fractional short-
ening and tended toward improvement in patients with normal
baseline fractional shortening (81).
In the largest series of 23 patients with AF and rest average
ventricular rates.100 beats/min, New York Heart Association
functional class decreased significantly, and exercise time
increased significantly, with AV junction ablation and perma-
nent ventricular pacing (82). Subgroup analysis demonstrated
that in patients with decreased left ventricular systolic function,
fractional shortening increased, whereas in subjects with nor-
mal baseline left ventricular systolic function, fractional short-
ening decreased significantly. These findings lead the authors
to view treatment of drug-refractory AF patients as a balance
between the benefits of rate control versus the possible dele-
terious hemodynamic effects of right ventricular pacing.
In addition to control of AF rapid ventricular responses,
preliminary human data suggest that the irregularity of AF
despite “controlled” ventricular rates may contribute to ven-
tricular dysfunction (83–85). A comparison of pharmacologic
ventricular rate control versus ventricular rate control plus
regularization of rhythm through AV junction ablation and
permanent cardiac pacing would help to assess the contribu-
tion of irregularity of rhythm to ventricular dysfunction.
Data supporting tachycardia-induced cardiomyopathy have
also been provided through assessment of the impact of
control of supraventricular tachycardias due to accessory AV
pathways and AV node reentrant tachycardia on left ventric-
ular function (67,72,86). In a study of subjects with frequent
episodes of tachycardia due to accessory pathways or AV node
reentry treated with direct current or radiofrequency energy
catheter ablation, there was significant improvement in frac-
tional shortening, nuclear ejection fraction and New York
Heart Association functional class (86).
Indirect data that may support the concept that increased
heart rate can exacerbate or contribute to left ventricular
dysfunction are beta-adrenergic blocking agent trials in chronic
heart failure. In these trials, beta-blockers were associated with
significant reduction in heart rate and improvement of hemo-
dynamic function and heart failure symptoms (87,88). How-
ever, it is unclear from the current data whether the reduction
in heart rate contributes to improvement or merely reflects
improvement in heart failure caused by other mechanisms.
Limitations. These preliminary human data suggest that
supraventricular tachycardias due to rapid ventricular rates
and potentially due to irregularity of rhythm may impair left
ventricular systolic function in a reversible manner. However,
these conclusions are derived from small studies of heteroge-
neous patient samples using gross measures of left ventricular
function. Limitations in some studies include lack of control
for rhythm and ventricular rate during comparison of baseline
and posttherapy left ventricular function and lack of control
for withdrawal of negative inotropic medications. The possible
improvement in ventricular function in patients with heart
failure and tachycardia rhythm or rate control requires pro-
spective confirmation in larger numbers of patients using
currently available treatment modalities and needs to address
issues relating to tachycardia-induced cardiomyopathy mecha-
nisms, patient groups affected and optimal therapies. Despite
abundant data from animal models of tachycardia-induced
cardiomyopathy, there are no significant data on the time
course, mechanisms or biochemical changes of tachycardia-
induced cardiomyopathy in humans. The relevance of animal
models to the human condition has not been established.
Table 1. Effect of Atrial Fibrillation Rhythm or Rate Control on Left Ventricular Systolic Function
Study (ref no.)
No. of
Pts.
Intervention
Type
Method of
Assessment
Pre
(%)
Post
(%)
p
Value
Kieny et al. (74) 12 CV EF 32 6 5 53 6 10 , 0.001
Van Gelder et al. (75) 8 CV EF 36 6 13 53 6 8 , 0.05
Twidale et al. (76) 14 AVJ EF 42 6 3 47 6 4 , 0.05
Heinz et al. (77) 10 AVJ FS 286 9 35 6 8 , 0.01
Brignole et al. (78) 9* AVJ FS 236 5 31 6 9 , 0.01
13† AVJ FS 40 6 5 36 6 6 0.05
*Patients (Pts) with depressed baseline fractional shortening (FS). †Patients with normal baseline fractional
shortening. AVJ 5 atrioventricular junction ablation and permanent pacemaker; CV 5 cardioversion; EF 5 ejection
fraction; ref 5 reference.
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Clinical implications. The current published reports focus
primarily on patients with a presumed diagnosis of “idio-
pathic” dilated cardiomyopathy with complete reversibility
of ventricular dysfunction with tachycardia rate and rhythm
control. Characterization of patients with a “pure” reversible
tachycardia-induced cardiomyopathy and differentiation from
other patients with dilated cardiomyopathy require investiga-
tion. An issue with wider potential ramifications is whether
patients with common etiologies of dilated cardiomyopathy
may have an additional reversible component of ventricular
dysfunction due to tachyarrhythmias. The identification of
patient subsets with common etiologies of heart failure who
have some reversibility of ventricular dysfunction with rhythm
or rate control, as well as the magnitude of their improvement,
requires further investigation. Specifically in regard to patients
with antiarrhythmic refractory AF and rapid ventricular re-
sponses in the setting of depressed ventricular function, con-
trolled clinical trials are necessary to assess which therapeutic
modality (pharmacologic or AV junction ablation and perma-
nent pacemaker placement) achieves optimal rate control and
optimal systolic function. Because the minimal rate and dura-
tion of tachycardia required to induce cardiomyopathy are
currently unknown, there could conceivably be a relatively
rapid progression to worsening cardiac function in patients
with tachyarrhythmias. Until more data are available, heart
rate and rhythm control should be rigorously and rapidly
pursued if definite signs of a cardiomyopathic process have
developed.
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